WFH NETWORK

Presentations from the seventh WFH Global Forum
September 22-23, 2011

Thursday, September 22


Perspectives on risk

Judie Leach Bennett, Candian Blood Services
Risk-based decision making for blood safety: An international consensus conference – report and future steps. Presentation

Mark W. Skinner, World Federation of Hemophilia
MSM donor deferral. Presentation

Nathan Schaefer, MSSA, Gay Men’s Health Crisis
Advocacy to revise blood donation policies for MSM. Presentation

Steven Kleinman, Blood Systems Research Institute
HIV data from a multicenter efficacy study of HIV, HCV, and HBV blood screening scenarios. Presentation

Achieving a safe and affordable supply

Health technology assessment in hemophilia

Albert Farrugia, Plasma Protein Therapeutics Association
Hemophilia and health technology assessment. Presentation

Update on inhibitors

J. Michael Soucie, Centers for Disease Control and Prevention
Update on studies of inhibitors. Presentation

Carol K. Kasper, University of Southern California
How do we define a (clinically-relevant) inhibitor? Presentation

Corien Eckhardt, INSIGHT investigators
Inhibitor development in mild/moderate hemophilia A. Presentation

Elena Santagostino, Milan, Italy
SIPPET and EUHASS studies. Presentation

Clinica trial issues

Jerry S. Powell, Hemostasis and Thrombosis Center, University of California Davis
New products for treatment of hemophilia ‒ changing options and clinical trial design. Presentation

Donna Di Michele, project group of the FVIII/IX subcommittee
Clinical trial design for hemophilia. Presentation

Alok Srivastava, on behalf of the FVIII/IX sub-committee SSC-ISTH project group
Potency assignment of clotting factor concentrates. Presentation


Friday, September 23


Novel technologies

Magdy El Ekiaby, Shabrawishi Hospital BTC
SD Cryoprecipitate: Clinical experience update. Presentation

Manufacturer's updates

Debra Bensen-Kennedy, CSL Behring
Pioneering designs for recombinant coagulation factors. Presentation

Prasad Mathew, Bayer
Novel treatment options for hemophilia treatment. Presentation

Snejana Krassova, Biogen Idec Hemophilia
Research update. Presentation

Kim Jacobsen, Novo Nordisk
Manufacturing, efficacy and safety of recombinant FXIII. Presentation


Updated May 2012